ATCC Number：CRL-9068?
數(shù)量：大量
相關(guān)疾?。憾喟l(fā)性骨髓瘤
細(xì)胞類型：B淋巴細(xì)胞
是否是腫瘤細(xì)胞：1
物種來源：人
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞形態(tài)：淋巴樣
NCI-H929 [H929] cells are B lymphocytes isolated from a malignant effusion in a 62-
year-old, White, female plasmacytoma myeloma patient. Use these cells in cancer
and immunology research. This product is an ATCC manufactured and accessioned
progeny of ATCC CRL-9068 cited in US Pat. No. 4,892,829.
免疫類型：IgA kappa (Recent tests for IgA, kappa have not detected the production of IgA; the cells are producing kappa light chain.)
年限：62 years
器官來源：骨髓
生長狀態(tài)：懸浮生長
規(guī)格：0.1ml Designations: NCI-H929 [H929]
Depositors: ?National Cancer Institute
Isotype: IgA kappa (Recent tests for IgA, kappa have not detected the production of IgA; the cells are producing kappa light chain.)
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: bone marrow
Disease: plasmacytoma; myeloma
Cell Type: B lymphocyte;
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:transferrin
Antigen Expression:PCA-1; CD38 +
DNA Profile (STR):Amelogenin: X
CSF1PO: 11
D13S317: 12
D16S539: 9,13
D5S818: 11,12
D7S820: 10,12
THO1: 9.3
TPOX: 8,11
vWA: 14,15
Cytogenetic Analysis:Near tetraploid. Most copies of chromosome 8 have the 8q+ abnormality.
Age: 62 years
Gender: female
Ethnicity: Caucasian
Comments:This cell line was established from a malignant effusion in a patient with myeloma.
The cells are positive for plasma cell antigen 1 (PCA-1), transferrin receptor, CD38 (T10), but are negative for HLA DR, CALLA and markers of early B cell development.
They are negative for Epstein-Barr virus nuclear antigen (EBNA).
The cells have a rearrangement of the c-myc proto oncogene and express c-myc RNA.
There is also an activated ras allele.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 2-mercaptoethanol to a final concentration of 0.05 mM; fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 4 X 10(5) viable cells/ml.
Interval: Maintain cultures at cell concentrations between 5 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: 2 to 3 times per week
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 22372: Hollis GF, et al. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol. Cell. Biol. 8: 124-129, 1988. PubMed: 3275865
23349: Gazdar AF, et al. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67: 1542-1549, 1986. PubMed: 2423157
23351: Ernst TJ, et al. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72: 1163-1167, 1988. PubMed: 3048435
